spacer
home > ebr > autumn 2018 > novel tff capsule evaluation
PUBLICATIONS
European Biopharmaceutical Review

Novel TFF Capsule Evaluation

Antibody-drug conjugates (ADCs) are a promising class of cancer chemotherapeutics. These drugs consist of a tumour-specific monoclonal antibody (mAb) conjugated to a highly potent cytotoxic agent via a stable linker molecule. The attached cytotoxin presents a unique safety challenge for chemotherapeutic ADC manufacturing compared to traditional mAb production, particularly regarding operator exposure. To mitigate exposure risk, manufacturers are adopting single-use components in post-conjugation stages of ADC production. Specifically, single-use tangential flow filtration (TFF) systems enable the safe production of cytotoxic ADCs. In this study, the performance of a novel single-use TFF capsule was compared with a traditional, multi-use TFF cassette in an ADC process. The data demonstrated that the single-use TFF capsule delivered performance standards equivalent to a TFF cassette while providing superior ease of use. This novel capsule represents a new generation of single-use TFF devices to improve safety and ease of use.

ADCs represent a modern application of Paul Ehrlich’s magic bullet concept (1). A tumour-specific antibody attached to a cytotoxic drug selectively delivers a toxic agent to a specific cancerous cell type in the body, triggering its death. Therefore, ADCs combine the delivery and cancer-killing functions of a drug in a single molecule (2). ADC development and manufacturing is a booming area of commercial activity with more than 50 ongoing clinical trials and four validated drugs brought to market in 2000, 2011, 2013, and 2017 (3-6).

By nature, ADCs are complex entities, and less than 2% of the administered dose reaches the target. This low-targeting efficiency requires that ADCs contain a highly active pharmaceutical ingredient (HAPI) payload when they do reach their intended targets (7). HAPI occupational exposure limits for a single worker employed at eight hours a day for 40 hours a week must be less than one microgram per cubic metre (8-10). These low maximum exposure levels pose significant challenges during manufacturing. Furthermore, classical ADC processes involve the use of aqueous buffers and excipients prone to microbiological contamination and organic solvents (typically dimethyl sulfoxide [DMSO] and dimethylacetamide [DMAC]), all of which present additional health concerns.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marc Frederic is head of a process development lab for the Sanofi bio-organic team, who are dedicated to protein conjugates to support research programmes leading to commercial launch readiness. Marc is an experiment design expert and has a technical chemistry background.

Dr Eric Lacoste is head of the Sanofi bio-organic team. He is in charge of the supervision of process development for protein conjugates to support research programmes leading to commercial launch readiness. Eric is responsible for process transfer and overseeing current Good Manufacturing Practice (cGMP) manufacturing. He holds a PhD in organic chemistry.

Philippe Masson is a technician for the Sanofi bio-organic team and is an expert in chemical engineering.

Catherine Souder is head of a process development lab for the Sanofi bio-organic team. Catherine is also responsible for process transfer and overseeing cGMP manufacturing, and has a technical chemistry background.

Jonathan Steen is a principal engineer leading TFF Applications R&D for Merck. He holds a BS in chemical engineering, is a licensed professional engineer, and has over 20 years of experience developing tangential flow filtration solutions for biopharmaceutical applications.

Alexandre Laly holds a BS in biochemistry and an MS in biological engineering, specialising in pharmaceutical bioprocesses. Alexandre has worked at Merck Group since 2015 as a Technology Manager, specialising in filtration technologies covering Europe, the Middle East, and Africa.
spacer
Marc Frederic
spacer
spacer
spacer
Dr Eric Lacoste
spacer
spacer
spacer
Philippe Masson
spacer
spacer
spacer
Catherine Souder
spacer
spacer
spacer
Jonathan Steen
spacer
spacer
spacer
Alexandre Laly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up • Tailored upstream development from a single source reduces time to clinic by 20 percent • Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement